Skip to content
All Sections
Subscribe Now
64°F
Thursday, October 3rd 2024
e-Edition
Home Page
Close Menu
News
News
Crime and Public Safety
Investigative Reporting
Politics
Health
Environment
Business
Best Reviews
Housing
Jobs
Local News
Local News
Long Beach
Los Angeles
Los Angeles County
Sports
Sports
High School Sports
Chargers
Rams
Lakers
Clippers
Dodgers
Angels
College Sports
UCLA Sports
USC Sports
Long Beach State sports
Kings
Ducks
Olympics
Boxing/MMA
Soccer
Horse Racing
Things To Do
Things To Do
Restaurants Food and Drink
Movies
Music + Concerts
Theater
TV and Streaming
Home + Garden
Travel
Amusement Parks
Comics
Puzzles
Events
Obituaries
Obituaries
News Obituaries
Place an Obituary
Opinion
Opinion
Editorials
Opinion Columns
Commentary
Letters to the Editor
Editorial Board
Endorsements
The Grunion
The Grunion
News
Education
Sports
Things to Do
Opinion
E-Edition
Advertising
Contact Us
SCNG Premium
The T.E.A.
Subscribe
Press-Telegram Store
Log In
Logout
Close Menu
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Account Settings
Contact Us
Log Out
Spoof a user
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Search
Press Telegram
64°F
Thursday, October 3rd 2024
e-Edition
News
Local News
Sports
Things to Do
Obituaries
Opinion
The T.E.A.
Trending:
DMV scraps test for some
Man hit, killed by fire engine
Disney price bump to come?
Affordable senior housing opens
High School Football
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Seres Therapeutics, Inc.
< Previous
1
2
3
Next >
Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference
August 04, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
August 03, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Host Second Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2022
July 28, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Announces $100 Million Registered Direct Offering of Common Stock
June 30, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection
June 07, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
June 01, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
May 22, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
May 10, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
May 04, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Host First Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2022
April 28, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting
March 18, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Host Fourth Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on March 1, 2022
February 22, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer
February 08, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Host Virtual Investor Event Highlighting Opportunities for Microbiome Therapeutics in Infection Protection on January 31, 2022
January 24, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
New England Journal of Medicine Publishes Data from ECOSPOR lll Phase 3 Study Evaluating Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection
January 19, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Announces Preliminary SER-287 Phase 2b ECO-RESET Study Microbiome Data Analysis
December 16, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Announces First Patient Enrolled in Phase 1b Study of SER-155, an Investigational Microbiome Therapeutic to Reduce the Risk of Antibiotic-Resistant Bacterial Infections and Graft-Versus-Host Disease (GvHD)
November 30, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
November 24, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
November 10, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Host Third Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on November 10, 2021
November 04, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Presents Late-Breaking Phase 3 Data on Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection at American College of Gastroenterology 2021 Annual Scientific Meeting
October 26, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Presents Late-Breaking Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at IDWeek2021
October 02, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Presents Data Supporting its Microbiome Pipeline at IDWeek 2021, Including Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection
September 29, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Achieves Enrollment of 300 Subjects with Phase 3 ECOSPOR IV Open-Label Extension Study of SER-109, a Potentially First-in-Class Investigational Microbiome Therapeutic for Recurrent C. difficile Infection
September 15, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences
September 07, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
August 05, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
August 03, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Host Second Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2021
July 29, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2b Study of SER-287 to Treat Mild-to-Moderate Ulcerative Colitis
July 22, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close